
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Human Cancer Biology |
Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland
Requests for reprints: Ira Pastan, Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, 37 Convent Drive, Room 5106, Bethesda, MD 20892-4264. Phone: 301-496-4797; Fax: 301-402-1344; E-mail: pastani{at}mail.nih.gov.
Purpose: The immunoglobulin superfamily receptor translocation associated 2 (IRTA2) gene encodes a cell surface receptor homologous to the family of Fc receptors. Because of the restricted expression of mRNA in B celllineage cells, IRTA2 is a new potential target for the immunotherapy of B cell malignancies. To study the expression of the IRTA2 gene product, we produced monoclonal antibodies (MAbs) specific to IRTA2.
Experimental Design: A mouse used for cell fusion was DNA-immunized with an expression plasmid encoding the IRTA2 cDNA. The reactivity of MAbs secreted from the hybridomas were characterized with recombinant proteins of IRTA family members in an enzyme immunoassay and a fluorescence-activated cell sorter (FACS). Nineteen human lymphoma cell lines and blood cells from five patients with hairy cell leukemia (HCL) were analyzed with IRTA2 expression using FACS.
Results: Three MAbs (F25, F56, and F119) were selected based on their specific reactivity with recombinant IRTA2 and lack of cross-reactivity with other IRTA family members. In a FACS analysis, MAbs F56 and F119 detected IRTA2 expression in six of seven B cell nonHodgkin's lymphoma and one of six Burkitt's lymphoma cell lines. Reverse transcriptase-PCR experiments and Western blotting using MAb F25 confirmed the expression profile. We also found that HCL cells from five patients expressed IRTA2.
Conclusions: Our results provide the first evidence that IRTA2 is expressed on the surface of human lymphoma cell lines and HCL cells. IRTA2 could be useful as a new target for immunotherapy.
Key Words: BXMAS1 FcRH5 B cell nonHodgkin's lymphoma immunotherapy
This article has been cited by other articles:
![]() |
F. J. Li, S. Ding, J. Pan, M. A. Shakhmatov, E. Kashentseva, J. Wu, Y. Li, S.-j. Soong, N. Chiorazzi, and R. S. Davis FCRL2 expression predicts IGHV mutation status and clinical progression in chronic lymphocytic leukemia Blood, July 1, 2008; 112(1): 179 - 187. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Du, S. Nagata, T. Ise, M. Stetler-Stevenson, and I. Pastan FCRL1 on chronic lymphocytic leukemia, hairy cell leukemia, and B-cell non-Hodgkin lymphoma as a target of immunotoxins Blood, January 1, 2008; 111(1): 338 - 343. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. L. Haga, G. R. A. Ehrhardt, R. J. Boohaker, R. S. Davis, and M. D. Cooper Fc receptor-like 5 inhibits B cell activation via SHP-1 tyrosine phosphatase recruitment PNAS, June 5, 2007; 104(23): 9770 - 9775. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Onda, S. Nagata, D. J. FitzGerald, R. Beers, R. J. Fisher, J. J. Vincent, B. Lee, M. Nakamura, J. Hwang, R. J. Kreitman, et al. Characterization of the B Cell Epitopes Associated with a Truncated Form of Pseudomonas Exotoxin (PE38) Used to Make Immunotoxins for the Treatment of Cancer Patients J. Immunol., December 15, 2006; 177(12): 8822 - 8834. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Mohan, J. Dement-Brown, S. Maier, T. Ise, B. Kempkes, and M. Tolnay Epstein-Barr virus nuclear antigen 2 induces FcRH5 expression through CBF1 Blood, June 1, 2006; 107(11): 4433 - 4439. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. R.A. Ehrhardt, J. T. Hsu, L. Gartland, C.-M. Leu, S. Zhang, R. S. Davis, and M. D. Cooper Expression of the immunoregulatory molecule FcRH4 defines a distinctive tissue-based population of memory B cells J. Exp. Med., September 19, 2005; 202(6): 783 - 791. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Nagata, T. Ise, M. Onda, K. Nakamura, M. Ho, A. Raubitschek, and I. H. Pastan Cell membrane-specific epitopes on CD30: Potentially superior targets for immunotherapy PNAS, May 31, 2005; 102(22): 7946 - 7951. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |